EP1, a rabbit monoclonal antibody, recognizes the epitopes of human ER alpha. This antibody stains nuclei of breast epithelial cells and breast carcinomas, as well as cervix, ovary, uterus, and prostate. Estrogen receptor (ER) expression has long been considered to be present in approximately two-thirds of breast cancers.sup> It has been demonstrated that patients with ER-positive tumors have a better prognosis than patients with ER-negative tumors. In the case of anti-ER, 1% of positively labeled cells within a tumor has been established as the cut-off for tumor positivity. A recent study of 314 cases has reported that the EP1 clone shows a very strong overall agreement with the commonly used SP1 clone. The EP1 clone is a very useful rabbit monoclonal antibody in the characterization of breast carcinoma.
EP1, a rabbit monoclonal antibody, recognizes the epitopes of human ER alpha. This antibody stains nuclei of breast epithelial cells and breast carcinomas, as well as cervix, ovary, uterus, and prostate. Estrogen receptor (ER) expression has long been considered to be present in approximately two-thirds of breast cancers.sup> It has been demonstrated that patients with ER-positive tumors have a better prognosis than patients with ER-negative tumors. In the case of anti-ER, 1% of positively labeled cells within a tumor has been established as the cut-off for tumor positivity. A recent study of 314 cases has reported that the EP1 clone shows a very strong overall agreement with the commonly used SP1 clone. The EP1 clone is a very useful rabbit monoclonal antibody in the characterization of breast carcinoma.
http://www.cellmarque.com/Cell Marque
EP1, a rabbit monoclonal antibody, recognizes the epitopes of human ER alpha. This antibody stains nuclei of breast epithelial cells and breast carcinomas, as well as cervix, ovary, uterus, and prostate. Estrogen receptor (ER) expression has long been considered to be present in approximately two-thirds of breast cancers.sup> It has been demonstrated that patients with ER-positive tumors have a better prognosis than patients with ER-negative tumors. In the case of anti-ER, 1% of positively labeled cells within a tumor has been established as the cut-off for tumor positivity. A recent study of 314 cases has reported that the EP1 clone shows a very strong overall agreement with the commonly used SP1 clone. The EP1 clone is a very useful rabbit monoclonal antibody in the characterization of breast carcinoma.
